Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNM NASDAQ:CRDL NASDAQ:IMUX NASDAQ:SPRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.26+5.0%$1.15$0.95▼$1.95$37.65M-0.11161,762 shs131,972 shsCRDLCardiol Therapeutics$1.31-1.5%$1.21$0.88▼$1.71$148.72M0.77711,552 shs438,247 shsIMUXImmunic$11.28+6.2%$11.10$5.06▼$15.10$144.66M1.2340,048 shs272,876 shsSPROSpero Therapeutics$2.42-3.2%$2.50$0.57▼$3.22$144.75M1.43476,060 shs505,629 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals+11.50%+5.88%+28.52%+8.62%-16.00%CRDLCardiol Therapeutics-4.38%-4.38%-7.09%+29.70%+13.91%IMUXImmunic+16.89%+4.93%-2.76%+81.91%+0.71%SPROSpero Therapeutics-2.42%-9.36%-0.41%+5.68%+296.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.26+5.0%$1.15$0.95▼$1.95$37.65M-0.11161,762 shs131,972 shsCRDLCardiol Therapeutics$1.31-1.5%$1.21$0.88▼$1.71$148.72M0.77711,552 shs438,247 shsIMUXImmunic$11.28+6.2%$11.10$5.06▼$15.10$144.66M1.2340,048 shs272,876 shsSPROSpero Therapeutics$2.42-3.2%$2.50$0.57▼$3.22$144.75M1.43476,060 shs505,629 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals+11.50%+5.88%+28.52%+8.62%-16.00%CRDLCardiol Therapeutics-4.38%-4.38%-7.09%+29.70%+13.91%IMUXImmunic+16.89%+4.93%-2.76%+81.91%+0.71%SPROSpero Therapeutics-2.42%-9.36%-0.41%+5.68%+296.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 3.00Buy$4.50257.14% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50548.85% UpsideIMUXImmunic 3.00Buy$52.43364.79% UpsideSPROSpero Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest ATNM, CRDL, SPRO, and IMUX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/4/2026IMUXImmunic Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/30/2026IMUXImmunic HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00 ➝ $22.004/21/2026SPROSpero Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026IMUXImmunic Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$25.004/15/2026IMUXImmunic D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold4/6/2026CRDLCardiol Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.003/31/2026ATNMActinium Pharmaceuticals StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$5.003/24/2026IMUXImmunic GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.003/2/2026IMUXImmunic HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $50.002/13/2026IMUXImmunic D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$80.00 ➝ $40.002/10/2026CRDLCardiol Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium Pharmaceuticals$90K439.25N/AN/A$1.31 per share0.96CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AIMUXImmunicN/AN/AN/AN/A($0.55) per shareN/ASPROSpero Therapeutics$66.80M2.10$0.15 per share16.43$1.05 per share2.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.08N/AN/AN/AN/A-100.85%-47.89%N/ACRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-239.10%-165.77%5/13/2026 (Estimated)IMUXImmunic-$97.17M-$7.00N/AN/AN/AN/A-1,197.81%-264.95%5/7/2026 (Estimated)SPROSpero Therapeutics$8.57M$0.1220.17N/AN/A12.83%22.53%13.04%5/13/2026 (Estimated)Latest ATNM, CRDL, SPRO, and IMUX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026CRDLCardiol Therapeutics-$0.07N/AN/AN/AN/AN/A5/13/2026Q1 2026SPROSpero Therapeutics-$0.18N/AN/AN/A$43.34 millionN/A5/7/2026Q1 2026IMUXImmunic-$0.71N/AN/AN/AN/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/26/2026Q4 2025SPROSpero Therapeutics-$0.20$0.53+$0.73$0.53$26.00 million$41.30 million2/26/2026Q4 2025IMUXImmunic-$1.0222-$1.20-$0.1778-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ASPROSpero TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25CRDLCardiol TherapeuticsN/A4.164.16IMUXImmunicN/A0.750.75SPROSpero TherapeuticsN/A7.597.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%CRDLCardiol Therapeutics12.49%IMUXImmunic51.82%SPROSpero Therapeutics25.60%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals0.60%CRDLCardiol Therapeutics5.25%IMUXImmunic14.00%SPROSpero Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.38 million29.32 millionOptionableCRDLCardiol Therapeutics20111.82 million105.95 millionNot OptionableIMUXImmunic7013.62 million11.72 millionOptionableSPROSpero Therapeutics15057.90 million54.72 millionOptionableATNM, CRDL, SPRO, and IMUX HeadlinesRecent News About These CompaniesSpero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026May 5 at 4:05 PM | globenewswire.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short InterestApril 30, 2026 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving Average - What's Next?April 16, 2026 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 50-Day Moving Average - Time to Sell?April 7, 2026 | marketbeat.comSpero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business UpdateMarch 26, 2026 | globenewswire.comSpero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026March 18, 2026 | globenewswire.comSpero Therapeutics: Tebipenem's FDA Path Supports A Speculative BuyFebruary 11, 2026 | seekingalpha.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $207,484.12 in StockFebruary 10, 2026 | insidertrades.comInsider Selling: Spero Therapeutics (NASDAQ:SPRO) Insider Sells 18,442 Shares of StockFebruary 6, 2026 | insidertrades.comWhy Spero Therapeutics, Inc.’s (SPRO) Stock Is Up 7.48%February 4, 2026 | aaii.comAFormer Spero execs fined by SEC over antibiotic efficacy claimsJanuary 20, 2026 | fiercebiotech.comFSpero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including PyelonephritisDecember 19, 2025 | globenewswire.comIs Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?December 15, 2025 | finance.yahoo.comSpero Therapeutics (SPRO) price target decreased by 20.00% to 4.08December 6, 2025 | msn.comSpero Therapeutics announces inducement grant under Nasdaq listing ruleNovember 29, 2025 | msn.comSpero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)November 28, 2025 | globenewswire.comSpero Therapeutics Focuses on Tebipenem HBr ProgramNovember 14, 2025 | msn.comSpero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business UpdateNovember 13, 2025 | globenewswire.comSpero Therapeutics (NASDAQ:SPRO) Insider Sells $95,439.90 in StockNovember 13, 2025 | insidertrades.comInsights Ahead: Spero Therapeutics's Quarterly EarningsNovember 13, 2025 | benzinga.comSpero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025November 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Investing in Rare Earth Elements: How the REXC ETF Bypasses China’s DominanceBy Jessica Mitacek | April 28, 2026ATNM, CRDL, SPRO, and IMUX Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.26 +0.06 (+5.00%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.26 +0.00 (+0.08%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Cardiol Therapeutics NASDAQ:CRDL$1.31 -0.02 (-1.50%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$1.30 -0.02 (-1.15%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Immunic NASDAQ:IMUX$11.28 +0.66 (+6.21%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$11.18 -0.10 (-0.85%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Spero Therapeutics NASDAQ:SPRO$2.42 -0.08 (-3.20%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$2.45 +0.03 (+1.24%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
